Barclays Gets Bullish On US Biotechnology Sector (BBH)
More News related to ACAD
- ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
- ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
- ACADIA Pharma (ACAD) to Cut Workforce by 50%
- Unusual 11 Mid-Day Movers 10/06: FONR, ICTG, ACAD, AVCT Higher; MNKD, VRNMD, ARP, PPD Lower
- ACADIA Pharmaceuticals (ACAD) Shares Rise Sharply on Pimavanserin Update
More News related to AMGN
- Amgen (AMGN) Announces Cancer Survival Results when Faced with Vectibix in Combination with FOLFOX
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Call for Applications: The Amgen Award for Science Teaching Excellence
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
More News related to ARNA
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
- New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life
- Arena Pharma (ARNA) Reports Pivotal BLOOM Phase III data
- Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with
Biotech HOLDRs (NYSE: BBH) is seeing some upside action today after the biotech industry received its second major upgrade in the past few weeks. The ETF is up 1% today.
Today, Barclays upgraded the US Biotechnology sector from Neutral to Positive, citing valuation and saying they see significant opportunity for the group into 2nd-half of 2009.
With the sector call, the firm also upgraded Biogen Idec (Nasdaq: BIIB) from Underweight to Equal Weight and raised its price target to $52.
The firm's top rated biotech picks in the sector include Amgen (Nasdaq: AMGN), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), Cephalon (Nasdaq: CEPH), Acadia (Nasdaq: ACAD), Arena (Nasdaq: ARNA), Rigel (Nasdaq: RIGL), Array (Nasdaq: ARRY), Onyx (Nasdaq: ONXX), Isis (Nasdaq: ISIS), Regeneron (Nasdaq: REGN)
Earlier in the month, Goldman Sachs upgraded U.S. Large Cap Biotechs to Neutral.
Related Categories
UpgradesStocks Mentioned
-0.07
+0.64Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
